Corcept Therapeutics Incorporated (CORT) Reports 105-Month Response in One Cancer Patient
Corcept Therapeutics (CORT) reported a single patient with metastatic vulvar cancer responded to relacorilant plus nab-paclitaxel for over 105 months. The patient remains in treatment with stable disease, but the company cautioned this is an early case and may not reflect broader outcomes.


